Search
Tirzepatide Treatment Options in Louisiana
A collection of 19 research studies where Tirzepatide is the interventional treatment. These studies are located in the Louisiana, United States. Tirzepatide is used for conditions such as Obesity, Overweight and Type 2 Diabetes.
1 - 12 of 19
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Therapy
Unique Treatment for High Blood Pressure
Worried about high blood pressure? Think beyond typical high blood pressure treatments.
People who may be candidates for this procedure:
• Are at least 18 years old
• Have been unable to manage their high blood pressure with medications or lifestyle changes alone¹
Learn about a safe and effective procedure that may help reduce high blood pressure. See if you qualify today.
¹ Kandzari DE, et al. J Am Coll Cardiol. Nov 7, 2023;82(19):1809-1823.
People who may be candidates for this procedure:
• Are at least 18 years old
• Have been unable to manage their high blood pressure with medications or lifestyle changes alone¹
Learn about a safe and effective procedure that may help reduce high blood pressure. See if you qualify today.
¹ Kandzari DE, et al. J Am Coll Cardiol. Nov 7, 2023;82(19):1809-1823.
Conditions:
High Blood Pressure
High Blood Pressure (& [Essential Hypertension])
High Blood Pressure (Hypertension).
Hypertension
Essential Hypertension
Featured Offer
Join Thousands Waiting for Retatrutide
Retatrutide could change the weight loss landscape. Unlike semaglutide or tirzepatide, it activates three hormone receptors simultaneously — and early data shows it:
✅ Outpaced existing GLP-1 medications for weight loss in clinical trials
✅ Improved blood sugar, blood pressure, and cholesterol beyond weight loss alone
✅ Delivered results with a simple once-weekly injection
✅ Now in Phase 3 trials with FDA submission expected in the next 1–2 years
Join the waiting list. One email when it launches — that's it.
✅ Outpaced existing GLP-1 medications for weight loss in clinical trials
✅ Improved blood sugar, blood pressure, and cholesterol beyond weight loss alone
✅ Delivered results with a simple once-weekly injection
✅ Now in Phase 3 trials with FDA submission expected in the next 1–2 years
Join the waiting list. One email when it launches — that's it.
Conditions:
Weight Loss
Featured Offer
Discover Affordable Semaglutide Providers
We Checked the Checkout Page on Every Semaglutide Provider. Here's What We Found.
There's a big difference between the price on a landing page and what you actually pay. We went all the way through checkout so you know exactly what to expect.
📋 5 providers ranked by true monthly cost
💵 Options starting as low as $149/month
🏥 Only licensed providers using FDA-registered pharmacies
⭐ Real Trustpilot scores included — including the ones with mixed reviews
🔒 Includes cancellation policy warnings so you don't get stuck
There's a big difference between the price on a landing page and what you actually pay. We went all the way through checkout so you know exactly what to expect.
📋 5 providers ranked by true monthly cost
💵 Options starting as low as $149/month
🏥 Only licensed providers using FDA-registered pharmacies
⭐ Real Trustpilot scores included — including the ones with mixed reviews
🔒 Includes cancellation policy warnings so you don't get stuck
Conditions:
Weight Loss
Morbid Obesity
Featured Offer
Discover The Best Tirzepatide Providers
Finding legit tirzepatide online shouldn't feel like a gamble — but with hundreds of providers out there, it often does. We ranked the top 10 so you don't have to.
✅ Providers starting at $242/month
✅ Only accredited, licensed compounding pharmacies
✅ Ranked by real pricing, not marketing promises
✅ Includes patient reviews & hidden fee warnings
✅ Updated for 2026
✅ Providers starting at $242/month
✅ Only accredited, licensed compounding pharmacies
✅ Ranked by real pricing, not marketing promises
✅ Includes patient reviews & hidden fee warnings
✅ Updated for 2026
Conditions:
Overweight
Overweight and Obesity
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial
Completed
The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/15/2025
Locations: Grace Research - Bossier, Bossier City, Louisiana +2 locations
Conditions: Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
Active Not Recruiting
The main purpose of this study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 74 weeks and may include up to 19 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Tandem Clinical Research, Marrero, Louisiana +1 locations
Conditions: Obesity
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight.
The maximum duration of this study is up to 61 weeks.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/22/2025
Locations: Care Access - New Iberia, New Iberia, Louisiana +1 locations
Conditions: Crohn's Disease, Obesity or Overweight
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Recruiting
The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight.
Participation in this study will last up to 61 weeks, including 52 weeks of treatment.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/22/2025
Locations: Care Access - New Iberia, New Iberia, Louisiana +1 locations
Conditions: Ulcerative Colitis, Obesity or Overweight
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
Active Not Recruiting
The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriasis and achieve weight reduction compared to when receiving ixekizumab.
Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label tr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: DelRicht Research, Baton Rouge, Louisiana +1 locations
Conditions: Psoriasis, Obesity
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
Recruiting
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity.
The study will last up to 12 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Accurate Clinical Research, Inc, Lake Charles, Louisiana
Conditions: Psoriatic Arthritis, Overweight or Obesity
Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese
Completed
A phase 2 study to evaluate the effects of apitegromab as an adjunctive therapy to GLP-1 receptor agonist therapy in subjects with overweight or obesity
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/14/2025
Locations: Tandem Clinical Research GI, LLC, Marrero, Louisiana
Conditions: Overweight and Obesity
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
Active Not Recruiting
The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriatic arthritis and achieve weight reduction compared to when receiving ixekizumab.
Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatmen... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/01/2025
Locations: Accurate Clinical Research, Inc, Lake Charles, Louisiana
Conditions: Psoriatic Arthritis, Obesity
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Active Not Recruiting
The main purpose of this study is to evaluate the safety and efficacy of tirzepatide in adolescents that have obesity or overweight with at least one weight-related comorbidity. The study will last approximately 90 weeks and may include up to 25 visits.
Participants who have completed the primary 72-week GPHP study and have been off treatment for no more than 12 weeks (including the 4-week safety follow-up period), will have the opportunity to receive an additional 156 weeks of treatment with t... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
06/20/2025
Locations: Pennington Biomedical Research Center, Baton Rouge, Louisiana
Conditions: Obesity, Overweight
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
Active Not Recruiting
The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Pennington Biomedical Research Center, Baton Rouge, Louisiana
Conditions: Obesity
Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over
Terminated
This study aims to find out how well a combination of oral azelaprag taken once a day (QD) or twice a day (BID), along with a weekly injection of tirzepatide, works for weight management in adults 55 years and older. The researchers are also looking at safety.
Estimated Study Length:
* with the optional prescreening, the study duration may be up to 48 weeks.
* the treatment duration will be 24 weeks followed by 12 weeks follow-up.
* the visit frequency will be every 2 weeks for the first 8 wee... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
03/11/2025
Locations: Site 101, Marrero, Louisiana
Conditions: Obesity
A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)
Completed
The purpose of this study is to see if the study drug, tirzepatide administered once weekly, is safe and effective as a treatment for Nonalcoholic Steatohepatitis (NASH).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/22/2025
Locations: Tandem Clinical Research, Marrero, Louisiana
Conditions: Nonalcoholic Steatohepatitis
1 - 12 of 19